Drug ‘significantly’ slows Alzheimer’s progression: Study A clinical trial of donanemab has now been peer reviewed and published, indicating it can decelerate decline in the disease’s early stages.
Researchers uncover alternate theory for Alzheimer’s disease Rather than tangles and plaques being the cause of the disease, researchers are exploring the issue of lysosomal storage.